TrialThe Lancet. Haematology2016

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.

Hannah Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.